A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Based on published data and according to the approved product label for ankylosing
spondylitis and psoriatic arthritis, it can be expected that adalimumab 40 mg every 14 days
should be effective in psoriatic arthritic patients with axial involvement.